The Oracle of Omaha’s annual event kicked off with wares from See’s Candies to the latest Squishmallows of Warren Buffett and Charlie Munger.
Schlagwort-Archiv: CNBC
Berkshire Hathaway’s big mystery stock wager could be revealed soon
Warren Buffett’s bet, shrouded in mystery, has captivated Berkshire Hathaway investors since first appearing in disclosures late last year.
Talent war between family offices and Wall Street drives up salaries
Wealthy families are spending an average of $3 million to run their family offices, according to a J.P. Morgan Private report, and the biggest cost is staffing.
Berkshire Hathaway operating earnings soar 39% as Buffett’s cash hoard swells to record $188 billion
Berkshire Hathaway reported a huge year-over-year increase in operating earnings in the first quarter, while its cash holdings bubbled to record levels.
Here’s what’s driving Friday’s stock action in Apple, Coterra and Eli Lilly
The Investing Club holds its „Morning Meeting“ every weekday at 10:20 a.m. ET.
‚Trader justice‘: Ex-SocGen trader fired for risky bets claims he was made a ’scapegoat‘
A former Societe Generale trader who was fired for unauthorized risky bets has lambasted the French bank for making him a „scapegoat.“
China’s automakers must adapt quickly or lose out on the EV boom in the face of regulatory scrutiny abroad and competition at home
Adoption of battery and hybrid-powered cars has surged in China, but an onslaught of new models has fueled a price war, while regulatory scrutiny grows abroad.
We’re raising our price target on Apple after its big earnings beat and raise
The consumer tech giant is as strong as ever, and we see positive catalysts ahead.
Coinbase reports first-quarter revenue beat after bitcoin rally leads to surge in profit
Coinbase’s quarterly results follow a big jump in the price of bitcoin from a year earlier, though the rally has stalled of late.
Amgen scraps experimental weight loss pill, moves forward with injection
Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.